Meboflur

Flurbiprofen, the active ingredient in Meboflur, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral formulation for oropharyngeal use. It provides analgesic and anti‑inflammatory effects for the relief of mild to moderate pain and inflammation.

GNH USA supplies Meboflur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Flurbiprofen is employed in several musculoskeletal and postoperative pain conditions, acting through inhibition of prostaglandin synthesis.

Rheumatoid arthritis: reduces joint inflammation and pain. Osteoarthritis: alleviates joint stiffness and discomfort. Post‑operative dental pain: provides short‑term relief after dental surgery.

Flurbiprofen may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dyspepsia: upset stomach or indigestion. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness. - Nausea: feeling of sickness. - Diarrhoea: loose stools. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Renal impairment: reduced kidney function. - Hepatotoxicity: liver enzyme elevation. - Severe hypersensitivity reactions: anaphylaxis or angioedema. - Cardiovascular events: increased risk of heart attack or stroke. - Blood dyscrasias: thrombocytopenia or leukopenia.

When using flurbiprofen, consider the following safety measures.

Assess renal function: monitor kidney parameters in patients with pre‑existing renal disease. Evaluate gastrointestinal risk: use with caution in individuals with a history of ulcers or bleeding. Check cardiovascular status: avoid in patients with uncontrolled hypertension or recent cardiac events. Review concomitant medications: assess for additive NSAID exposure. Avoid use in known hypersensitivity: discontinue if allergic reactions occur. Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Flurbiprofen can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Other NSAIDs or COX‑2 inhibitors: increased gastrointestinal toxicity. - Corticosteroids: synergistic ulcerogenic effect. - Selective serotonin reuptake inhibitors (SSRIs): elevated bleeding potential. - ACE inhibitors or diuretics: possible reduction in renal function.

Moderate Interactions (Monitor Closely): - Lithium: potential for increased lithium levels. - Methotrexate: reduced clearance leading to toxicity. - Cyclosporine: enhanced nephrotoxic risk. - Digoxin: possible increase in serum concentrations. - Diabetic agents: may affect glycemic control.